Cameron tells Starmer ‘progress possible' on dementia after loss of his mother
The former prime minister said that there is 'still a mountain to climb', as he recalled the 'full destructive force' of the illness.
Writing in the Sunday Times, Lord Cameron also announced that he had returned to his position as president of Alzheimer's Research UK, having stepped down when he became foreign secretary in 2023.
In 2015 I set a bold challenge: to find a treatment for dementia by 2025. A decade of progress has delivered this, but we still have a mountain to climb.
Today I'm proud to return as President of @AlzResearchUK, and more determined than ever. #ForACure. https://t.co/xivwUJCD2h
— David Cameron (@David_Cameron) March 9, 2025
Lord Cameron wrote: 'The very future of our health service rests on how we respond to the growing dementia crisis.
'In short, there is still a mountain to climb. But my message to Sir Keir Starmer and his team is that progress is possible if they're committed to it.'
He said that his 'dear mother' Mary Cameron died last month.
'We were in a lucky position as a family to be able to pay for carers in her home,' he said.
'But no matter how good the care, the full destructive force of Alzheimer's is shocking and saddening in equal measure. Memory goes; movement goes; eventually speech and almost all cognition and recall goes.'
Lord Cameron said that breakthroughs in treatment were too late for his mother, 'but soon that won't be the case for people living with dementia'.
Alzheimer's disease is a type of dementia. According to Alzheimer's Research, almost one million people in the UK have dementia.
Hilary Evans-Newton, chief executive at Alzheimer's Research UK, said: 'We are thrilled to welcome Lord Cameron back as president of Alzheimer's Research UK, continuing the vital mission he set in motion with the Prime Minister's Dementia Challenge.
'No world leader has done more to put dementia on the global agenda, helping to secure vital research funding and drive awareness of a condition that affects millions.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Smile Source Partners with SimplyTest to Bring Salivary Screening to 800+ Independent Dental Practices
SimplyTest Oral Health-PERIO gives dentists a new tool for personalized, preventive care SALT LAKE CITY, July 29, 2025--(BUSINESS WIRE)--SimplyTest®, a leader in salivary testing solutions, today announced a strategic partnership with Smile Source, the nation's largest network of independent dental practices, to deliver SimplyTest Oral Health-PERIO, a cutting-edge salivary testing solution, to more than 800 Smile Source member offices. "This partnership reflects a shared mission of our two organizations: to empower dentists with best-in-class tools that improve patient outcomes," said Justin Hunt, CEO of SimplyTest. "Smile Source is known for its high standards and rigorous vendor vetting. We're honored to be selected as their exclusive salivary screening partner, offering members access to PERIO through their trusted membership platform." This is the first salivary testing solution offered through Smile Source, underscoring the growing demand among private practitioners for integrated, preventive health solutions in dentistry. With PERIO, member dentists will be equipped to provide earlier, more precise care and expand their role in systemic health detection and personalized treatment. Periodontal disease doesn't just affect the mouth; it is a chronic, often silent condition with far-reaching consequences including strong links to Alzheimer's, diabetes, cardiovascular disease and cancer. PERIO helps dental professionals uncover what traditional exams may overlook. By detecting microbial risk factors early, clinicians can intervene sooner and educate patients more effectively to better support long-term health. "We're thrilled to welcome SimplyTest Oral Health-PERIO to the Smile Source family," said Tom Rimmer, Vice President of Strategic Partnerships at Smile Source. "This partnership gives our members access to a science-backed, noninvasive testing tool, which many have been asking for to elevate patient care. PERIO represents a meaningful advancement in their clinical capabilities, and we're excited to see its positive impact across the network." PERIO integrates advanced molecular testing into everyday dental workflows. A quick, pain-free saliva sample identifies key periodontal pathogens, caries-related organisms, Candida albicans and viruses associated with cognitive decline, cardiovascular disease and more. A patented buffer solution stabilizes samples at room temperature, making the test easy to implement and practical for busy practices. PERIO represents a shift toward smarter, evidence-based care. For Smile Source members, it not only enhances treatment outcomes at the chair, but also elevates their role as vital contributors to their patients' overall health. About Smile Source Smile Source is the leading network of independent dental practices in the United States, supporting more than 800 independently owned offices with the collective power to compete, grow and thrive. Through access to proven technology, innovative clinical solutions, and shared business resources, Smile Source empowers dentists to elevate patient care, enhance profitability and protect their independence. To learn more, visit About SimplyTest SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, noninvasive screenings that empower health care providers, functional medicine practitioners and dental professionals to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. Built on the belief that better diagnostics lead to better outcomes, SimplyTest is advancing a smarter, data-driven model of dentistry where early insight is the first step in personalized care. To learn more, visit View source version on Contacts Media Contact: Tim Rush for 801-208-1100 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
an hour ago
- CNN
Dramatic lifestyle changes can fight early-stage Alzheimer's, study says. Here's how
Source: CNN As her memory faded from Alzheimer's disease in her late 50s, Tammy Maida began to lose track of her life. Car keys, eyeglasses and her purse disappeared multiple times a day. Key characters in novels she was reading were forgotten. Groceries were left in the garage. Keeping the books for the family's businesses became impossible. 'I honestly thought I was losing my mind, and the fear of losing my mind was frightening,' Maida told CNN Chief Medical Correspondent Dr. Sanjay Gupta in the 2024 CNN documentary 'The Last Alzheimer's Patient.' After 20 weeks in a randomized clinical trial designed to drastically change her diet, exercise, stress levels and social interactions, Maida's cognition improved. She was able to read and recall novels and correctly balance spreadsheets again. A blood test even found levels of amyloid, a hallmark of Alzheimer's disease, were retreating in her brain, according to the study published in June 2024. 'I'm coming back. It was really good — like I was prior to the disease being diagnosed,' Maida, now 68, told a researcher on the study. 'An older but better version of me.' Maida's cognition showed additional improvement, however, after she completed a total of 40 weeks of intensive lifestyle changes, said principal investigator Dr. Dean Ornish, a clinical professor of medicine at the University of California, San Francisco, and creator of the Ornish diet and lifestyle medicine program. Ornish gave a study update on Tuesday at the 2025 Alzheimer's Association International Conference in Toronto. While not everyone in the 26-person interventional group benefited, 46% showed improvement in three of four standardized tests, he said, including one that measures changes in memory, judgment and problem-solving as well as the ability to function at home, practice hobbies and practice personal hygiene. 'An additional 37.5% of people showed no decline in cognition during those 40 weeks,' Ornish said. 'Thus, over 83% of patients improved or maintained their cognition during the five-month program.' The new findings mirrored those of other studies on lifestyle interventions, he said, including the recent US POINTER study, the largest clinical trial in the United States to test moderate lifestyle interventions over two years in people who are at risk but do not yet have Alzheimer's disease. 'Our study complements these findings by showing, for the first time, that more intensive lifestyle changes may often stop or even begin to reverse the decline in cognition in many of those who already have Alzheimer's disease, and these improvements often continue over a longer period of time,' Ornish told CNN. And unlike available medications for Alzheimer's, he added, lifestyle changes have no side effects, such as bleeding and swelling in the brain that may occur with the newest class of drugs. EmblemHealth, a New York-based insurance company, announced Tuesday that it will be the first health insurer to cover the Ornish lifestyle medicine program for patients who have early-stage Alzheimer's disease. The lifestyle intervention Ornish created — which he calls 'eat well, move more, stress less and love more' — has been tested before. In 1990, Ornish showed for the first time in a randomized clinical trial that coronary artery disease could often be reversed with nothing more than diet, exercise, stress reduction and social support. The US Centers for Medicare and Medicaid Services, or CMS, declared in 2010 that Ornish's program for reversing heart disease was an 'intensive cardiac rehabilitation' and that it would be eligible for reimbursement under Medicare. Additional research has shown the same four-part program can lower blood sugars and heart disease risk in patients with diabetes, reduce prostate cancer cell growth, improve depression and even lengthen telomeres, the protective caps of chromosomes that are worn away by aging. During the Ornish intervention, one group of people consumed a strict vegan diet, did daily aerobic exercise, practiced stress reduction and engaged in online support groups. The rest of the participants were in a control group and were asked to not make any changes in their daily habits. Therapists led hour-long group sessions three times a week in which participants were encouraged to share their feelings and ask for support. Meditation, deep breathing, yoga and other ways to reduce stress took up another hour every day. The program also encouraged participants to prioritize good-quality sleep. Supplements were provided to everyone in the intervention group, including a daily multivitamin, omega-3 fatty acids with curcumin, coenzyme Q10, vitamin C and B12, magnesium, a probiotic, and Lion's mane mushroom. In addition to online strength training led by a physical trainer, people in the intervention attended hour-long video classes on vegan nutrition hosted by a dietitian. Then, to ensure a vegan diet was followed, all meals and snacks for both participants and their partners were delivered to their homes. Complex carbs found in whole grains, vegetables, fruits, tofu, nuts and seeds made up most of the diet. Sugar, alcohol and refined carbs found in processed and ultraprocessed foods were taboo. While calories were unrestricted, protein and total fat made up only some 18% of the daily caloric intake — far less than the typical protein intake by the average American, Ornish said. People in the intervention group who put the most effort into changing their lifestyle have the most improvement in their cognition, said Ornish, founder and president of the nonprofit Preventive Medicine Research Institute and coauthor of 'Undo It! How Simple Lifestyle Changes Can Reverse Most Chronic Diseases.' 'There was a statistically significant dose-response relationship between the degree of adherence to our lifestyle changes and the degree of improvement we saw on measures of cognition,' Ornish said. The 25 people in the study's original 20-week control group — who did not receive the intervention — had shown further cognitive decline during the program. They were later allowed to join the intervention for 40 weeks and significantly improved their cognitive scores during that time, Ornish said. It all makes sense, said co-senior study author Rudy Tanzi, an Alzheimer's researcher and professor of neurology at Harvard Medical School in Boston. 'If you picture a brain full of damage as a sink full of water, when you just turn off the tap, it takes a long time for that sink to slowly drain, right?' Tanzi told CNN in 2024. 'If you want the amyloid to go down in 20 weeks, as we found on one blood test, you're going to need a Roto-Rooter.' In the 2024 study, a blood test called plasma Aβ42/40 showed a significant improvement in the original intervention group. Aβ42/40 measures the level of amyloid in the blood, a key symptom of Alzheimer's. Tests that measure amyloid in different ways, however, did not show improvement, Dr. Suzanne Schindler, an associate professor of neurology at Washington University School of Medicine in St. Louis who specializes in blood biomarkers told CNN at the time. There was no significant change in a test for amyloid called p-tau 181, considered to be a superior measure of Alzheimer's risk, said Schindler, who was not involved in the study. Nor was there any change in glial fibrillary acidic protein, or GFAP, another blood biomarker that seems to correlate reasonably well with Alzheimer's disease. 'If one of these markers improves, you typically see all of them improve, so the fact they did not makes me wonder whether this effect is real,' Schindler said. 'If they were to repeat the study with a much larger population for a longer period of time, perhaps more change could be seen.' Over the complete 40-week program, however, a number of people in the intervention group did continue to improve their Aβ42/40 scores, according to the study update. 'Changes in amyloid — as measured as the plasma Aβ42/40 ratio — occur before changes in tau markers such as p-tau 218, so this is not surprising after only 40 weeks,' Ornish said. For Ornish, who has watched members of his family die from Alzheimer's disease, the study's results are important for one key reason — hope. 'So often when people get a diagnosis of dementia or Alzheimer's, they are told by their doctors that there is no future, 'It's only going to get worse, get your affairs in order.' That's horrible news and is almost self-fulfilling,' Ornish said. 'Our new findings empower patients who have early-stage Alzheimer's disease with the knowledge that if they make and maintain these intensive lifestyle changes, there is a reasonably good chance that they may slow the progression of the disease and often even improve it,' he said. 'Our study needs to be replicated with larger, more diverse groups of patients to make it more generalizable,' Ornish said. 'But the findings we reported today are giving many people new hope and new choices — and the only side effects are good ones.' See Full Web Article
Business Wire
2 hours ago
- Business Wire
Smile Source Partners with SimplyTest to Bring Salivary Screening to 800+ Independent Dental Practices
SALT LAKE CITY--(BUSINESS WIRE)--SimplyTest®, a leader in salivary testing solutions, today announced a strategic partnership with Smile Source, the nation's largest network of independent dental practices, to deliver SimplyTest Oral Health-PERIO, a cutting-edge salivary testing solution, to more than 800 Smile Source member offices. SimplyTest Oral Health-PERIO is the first salivary testing solution offered through Smile Source, underscoring the growing demand among private practitioners for integrated, preventive health solutions in dentistry. Share 'This partnership reflects a shared mission of our two organizations: to empower dentists with best-in-class tools that improve patient outcomes,' said Justin Hunt, CEO of SimplyTest. 'Smile Source is known for its high standards and rigorous vendor vetting. We're honored to be selected as their exclusive salivary screening partner, offering members access to PERIO through their trusted membership platform.' This is the first salivary testing solution offered through Smile Source, underscoring the growing demand among private practitioners for integrated, preventive health solutions in dentistry. With PERIO, member dentists will be equipped to provide earlier, more precise care and expand their role in systemic health detection and personalized treatment. Periodontal disease doesn't just affect the mouth; it is a chronic, often silent condition with far-reaching consequences including strong links to Alzheimer's, diabetes, cardiovascular disease and cancer. PERIO helps dental professionals uncover what traditional exams may overlook. By detecting microbial risk factors early, clinicians can intervene sooner and educate patients more effectively to better support long-term health. 'We're thrilled to welcome SimplyTest Oral Health-PERIO to the Smile Source family,' said Tom Rimmer, Vice President of Strategic Partnerships at Smile Source. 'This partnership gives our members access to a science-backed, noninvasive testing tool, which many have been asking for to elevate patient care. PERIO represents a meaningful advancement in their clinical capabilities, and we're excited to see its positive impact across the network.' PERIO integrates advanced molecular testing into everyday dental workflows. A quick, pain-free saliva sample identifies key periodontal pathogens, caries-related organisms, Candida albicans and viruses associated with cognitive decline, cardiovascular disease and more. A patented buffer solution stabilizes samples at room temperature, making the test easy to implement and practical for busy practices. PERIO represents a shift toward smarter, evidence-based care. For Smile Source members, it not only enhances treatment outcomes at the chair, but also elevates their role as vital contributors to their patients' overall health. About Smile Source Smile Source is the leading network of independent dental practices in the United States, supporting more than 800 independently owned offices with the collective power to compete, grow and thrive. Through access to proven technology, innovative clinical solutions, and shared business resources, Smile Source empowers dentists to elevate patient care, enhance profitability and protect their independence. To learn more, visit About SimplyTest SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, noninvasive screenings that empower health care providers, functional medicine practitioners and dental professionals to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. Built on the belief that better diagnostics lead to better outcomes, SimplyTest is advancing a smarter, data-driven model of dentistry where early insight is the first step in personalized care. To learn more, visit
